SI0854867T1 - Tetrahydroquinolines as nmda antagonists - Google Patents

Tetrahydroquinolines as nmda antagonists

Info

Publication number
SI0854867T1
SI0854867T1 SI9630523T SI9630523T SI0854867T1 SI 0854867 T1 SI0854867 T1 SI 0854867T1 SI 9630523 T SI9630523 T SI 9630523T SI 9630523 T SI9630523 T SI 9630523T SI 0854867 T1 SI0854867 T1 SI 0854867T1
Authority
SI
Slovenia
Prior art keywords
tetrahydroquinolines
nmda antagonists
nmda
antagonists
Prior art date
Application number
SI9630523T
Other languages
English (en)
Slovenian (sl)
Inventor
Fabio Romano Di
Simone Giacobbe
Barbara Bertani
Fabrizio Micheli
Original Assignee
Glaxosmithkline S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9519893.3A external-priority patent/GB9519893D0/en
Priority claimed from GBGB9617306.7A external-priority patent/GB9617306D0/en
Application filed by Glaxosmithkline S.P.A. filed Critical Glaxosmithkline S.P.A.
Publication of SI0854867T1 publication Critical patent/SI0854867T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI9630523T 1995-09-29 1996-09-26 Tetrahydroquinolines as nmda antagonists SI0854867T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9519893.3A GB9519893D0 (en) 1995-09-29 1995-09-29 Heterocyclic compounds
GBGB9617306.7A GB9617306D0 (en) 1996-08-17 1996-08-17 Heterocyclic compounds
PCT/EP1996/004206 WO1997012870A1 (en) 1995-09-29 1996-09-26 Tetrahydroquinolines as nmda antagonists
EP96933399A EP0854867B1 (en) 1995-09-29 1996-09-26 Tetrahydroquinolines as nmda antagonists

Publications (1)

Publication Number Publication Date
SI0854867T1 true SI0854867T1 (en) 2003-02-28

Family

ID=26307841

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9630523T SI0854867T1 (en) 1995-09-29 1996-09-26 Tetrahydroquinolines as nmda antagonists

Country Status (28)

Country Link
US (1) US5977136A (cs)
EP (1) EP0854867B1 (cs)
JP (1) JP4108123B2 (cs)
KR (1) KR100464895B1 (cs)
CN (1) CN1130346C (cs)
AP (1) AP876A (cs)
AR (1) AR005233A1 (cs)
AT (1) ATE221520T1 (cs)
AU (1) AU708148B2 (cs)
BR (1) BR9610733A (cs)
CA (1) CA2232509A1 (cs)
CZ (1) CZ292379B6 (cs)
DE (1) DE69622731T2 (cs)
DK (1) DK0854867T3 (cs)
EA (1) EA000875B1 (cs)
ES (1) ES2180799T3 (cs)
HU (1) HUP9900040A3 (cs)
IL (1) IL123322A0 (cs)
IS (1) IS4677A (cs)
MX (1) MX9801967A (cs)
NO (1) NO310355B1 (cs)
NZ (1) NZ319596A (cs)
PL (1) PL186781B1 (cs)
PT (1) PT854867E (cs)
SI (1) SI0854867T1 (cs)
TR (1) TR199800531T1 (cs)
TW (1) TW460465B (cs)
WO (1) WO1997012870A1 (cs)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9617305D0 (en) 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
GB9706294D0 (en) * 1997-03-26 1997-05-14 Glaxo Wellcome Spa Heterocyclic compound
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
TW555757B (en) * 1998-07-31 2003-10-01 Akzo Nobel Nv Aminomethylcarboxylic acid derivatives
CA2339662A1 (en) * 1998-08-07 2000-02-17 Takeda Chemical Industries, Ltd. Benzothiepin derivatives, their production and use
GB9929037D0 (en) 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
US7307075B2 (en) * 2001-12-28 2007-12-11 Acadia Pharmaceuticals Inc. Tetrahydroquinoline analogues as muscarinic agonists
DE10236910A1 (de) * 2002-08-12 2004-03-11 Grünenthal GmbH Substituierte 1,2,3,4-Tetrahydrochinolinderivate
RU2451014C2 (ru) * 2005-07-22 2012-05-20 Мотида Фармасьютикал Ко., Лтд. Новое производное гетероциклиден ацетамида
EP1908753B1 (en) * 2005-07-22 2014-12-17 Mochida Pharmaceutical Co., Ltd. Novel heterocyclidene acetamide derivative
CN102015722A (zh) * 2008-03-05 2011-04-13 贝林格尔.英格海姆国际有限公司 三环吡啶衍生物、包含此类化合物的药物、它们的用途及其制备方法
EP2286808A1 (en) * 2009-08-18 2011-02-23 Rheinische Friedrich-Wilhelms Universität Cytohesin inhibitors
IN2012DN06631A (cs) 2010-02-16 2015-10-23 Pfizer
EA201201160A1 (ru) 2010-02-19 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Трициклические производные пиридина, лекарственные средства, содержащие такие соединения, их применение и способ их получения
EP2760868B1 (en) 2011-08-17 2018-04-25 Boehringer Ingelheim International GmbH Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
WO2016114655A1 (en) * 2015-01-12 2016-07-21 Ry Pharma B.V. Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation
WO2017065602A1 (en) * 2015-10-13 2017-04-20 Ry Pharma B.V. Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69029668T2 (de) * 1989-03-08 1997-08-07 Merck Sharp & Dohme Tetrahydroquinolin-Derivate, verwendbar bei neurodegenerativen Krankheiten

Also Published As

Publication number Publication date
AU7214896A (en) 1997-04-28
HUP9900040A2 (hu) 1999-04-28
TW460465B (en) 2001-10-21
NZ319596A (en) 1999-09-29
EA000875B1 (ru) 2000-06-26
CA2232509A1 (en) 1997-04-10
WO1997012870A1 (en) 1997-04-10
JP4108123B2 (ja) 2008-06-25
TR199800531T1 (xx) 1998-06-22
CZ292379B6 (cs) 2003-09-17
EP0854867B1 (en) 2002-07-31
IS4677A (is) 1998-02-27
EA199800230A1 (ru) 1998-10-29
CN1202887A (zh) 1998-12-23
ATE221520T1 (de) 2002-08-15
PL325966A1 (en) 1998-08-17
EP0854867A1 (en) 1998-07-29
DE69622731T2 (de) 2003-02-20
ES2180799T3 (es) 2003-02-16
JPH11512728A (ja) 1999-11-02
CN1130346C (zh) 2003-12-10
AR005233A1 (es) 1999-04-28
NO981396L (no) 1998-05-27
CZ94098A3 (cs) 1998-07-15
HK1009133A1 (en) 1999-05-28
AP876A (en) 2000-09-27
AU708148B2 (en) 1999-07-29
AP9801212A0 (en) 1998-03-31
DE69622731D1 (de) 2002-09-05
KR19990063850A (ko) 1999-07-26
PT854867E (pt) 2002-12-31
KR100464895B1 (ko) 2005-05-16
PL186781B1 (pl) 2004-02-27
IL123322A0 (en) 1998-09-24
US5977136A (en) 1999-11-02
HUP9900040A3 (en) 2001-01-29
NO310355B1 (no) 2001-06-25
BR9610733A (pt) 1999-07-13
MX9801967A (es) 1998-08-30
NO981396D0 (no) 1998-03-27
DK0854867T3 (da) 2002-12-02

Similar Documents

Publication Publication Date Title
EG23913A (en) Estrogen agonists / antagonists
HU9603082D0 (en) Neurokinine (tachykinine) antagonists
IL124522A0 (en) Quinoline derivatives
HU9601529D0 (en) Pyrimidinedion-, pyrimidinetrion-, triazinedion-, tetrahydro-quinazolinedion- derivatives as alpha-adrenerg receptor antagonists
AU1842995A (en) N-acylpiperidine tachykinin antagonists
CY2505B1 (en) Quinoline derivatives as nk3 antagonists
AU4343796A (en) Tachykinin antagonists
HU9600663D0 (en) Endothelin-receptor antagonists
HU9601176D0 (en) Adhesion-receptor antagonists
SI0854867T1 (en) Tetrahydroquinolines as nmda antagonists
AP9901459A0 (en) Tetrahydroquinoline derivatives as eaa antagonists
AU3567195A (en) Neurokinin antagonists
AU6856796A (en) Des-arg9-bk antagonists
HU9503191D0 (en) Adhesion-receptor antagonists
ZA96237B (en) Substituted 2-pheylpyridines
GB9508786D0 (en) Substituted heterocycles
ZA96238B (en) Substituted 2-pheylpyridines
ZA969987B (en) Lh-rh antagonists
HUP9802915A3 (en) New staphylokinase derivatives
HU9602253D0 (en) Endothelin-receptor antagonists
SG72612A1 (en) Substituted azo-dicarbonylo derivatites
GB9506678D0 (en) Substituted 6-azacholesten-3-ones
AU699544B2 (en) Narcotic antagonist
HUP0000420A3 (en) Process for the preparation of nmda antagonists
GB9620837D0 (en) Improved stop collar